MedTrace Logo

Lesion Characteristics After Pulsed-Field Ablation in Patients With Atrial Fibrillation and a Left Common Ostium

NCT05812261 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-03-06

No results posted yet for this study

Summary

This study aims to investigate the lesion characteristics after pulmonary vein isolation using pulsed-field ablation in patients with atrial fibrillation and a common of the left pulmonary veins.

The main question it aims to answer is: In which percentage of the patients will pulsed field ablation result in successful isolation of the left common ostium?

Nineteen patients will be prospectively included in OLVG. All patients will be treated with pulsed-field ablation (routine care). After the ablation procedure, an electro-anatomical map will be created using the ablation catheter and a mapping system. This map will display the left atrium and the lesion in detail.

After the procedure, three experienced operators are asked to draw a line around the LCO in the anatomical map where they would have ablated if conventional radiofrequency ablation was used. The distance between the drawn line and the ablation lesion will be measured at three predefined points. The lesion is considered successful if the mean distance is within ±10mm at all measurement points.

Conditions

Interventions

OTHER

Creating an electro-anatomical map

After the routine pulsed-field ablation procedure, the operator will create an electro-anatomical map using the ablation catheter and a 3D mapping system.

Sponsors & Collaborators

  • OLVG

    collaborator NETWORK

  • Onze Lieve Vrouwe Gasthuis

    lead OTHER

Principal Investigators

  • Daniel Mol, PhD · OLVG

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-19
Primary Completion
2024-02-29
Completion
2024-02-29

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05812261 on ClinicalTrials.gov